See: [Bear CAR-T PMCC overview document](bear://x-callback-url/open-note?id=FFB85D8B-31F7-40C9-AC1F-6EE0151B525D) **Chimeric Antigen Receptor** (CAR) T-Cell therapy is a type of adoptive cellular therapy where a CAR gene is introduced into T-cells, allowing that T-cell to identify, bind to, and eradicate target cells with a particular antigen. CAR T-cell therapy is used for haematological malignancies such as relapsed B-cell [[Leukemia#ALL|ALL]], and B-cell [[Lymphoma]]. # Complications ![[Pasted image 20250427144929.png]] ## Cytokine release syndrome (CRS) ## Immune effector cell-associated neurotoxicity syndrome (ICANS) - CNS dysfunction following any immune-effector cell therapy - symptoms can be mild to severe or fatal - most cases of ICANS resolve. rarely the cognitive changes may be permanent - early manifestations are expressive dysphasia/aphasia, especially naming objects, tremor, impaired attention. - severe ICANS can have agitation, delirium, sleep disturbance, or seizures, and has resulted in death due to cerebral oedema in rare cases.